Therapeutic Novelties in Migraine: New Drugs, New Hope?

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2019 Apr 19

PMID 30995909

Citations 44

Authors

Thien Phu Do

Song Guo

Messoud Ashina

Affiliations

Soon will be listed here.

Abstract

Background: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.

Main Body: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.

Conclusion: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.

Citing Articles

Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement.

Swart E, Peasah S, Huang Y, Bensink M, Greco M, Manolis C J Manag Care Spec Pharm. 2025; 31(3):236-244.

PMID: 40021466 PMC: 11871164. DOI: 10.18553/jmcp.2025.31.3.236.

GPT meets PubMed: a novel approach to literature review using a large language model to crowdsource migraine medication reviews.

Mackenzie E, Cheng R, Zhang P BMC Neurol. 2025; 25(1):69.

PMID: 39972406 PMC: 11837380. DOI: 10.1186/s12883-025-04071-1.

Proteome-wide Mendelian randomization identified potential drug targets for migraine.

Xiong Z, Zhao L, Mei Y, Qiu D, Li X, Zhang P J Headache Pain. 2024; 25(1):148.

PMID: 39261750 PMC: 11389401. DOI: 10.1186/s10194-024-01853-9.

Upholding or Breaking the Law of Superposition in Pharmacokinetics.

Yousef M, Yanez J, Lobenberg R, Davies N Biomedicines. 2024; 12(8).

PMID: 39200307 PMC: 11351987. DOI: 10.3390/biomedicines12081843.

Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine.

Sun X, Chen B, Qi Y, Wei M, Chen W, Wu X J Headache Pain. 2024; 25(1):117.

PMID: 39039470 PMC: 11265128. DOI: 10.1186/s10194-024-01828-w.

References

Nilsson T, Longmore J, Shaw D, Pantev E, BARD J, Branchek T . Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999; 372(1):49-56. DOI: 10.1016/s0014-2999(99)00114-4. View

Vaudry D, Gonzalez B, Basille M, Yon L, Fournier A, Vaudry H . Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000; 52(2):269-324. View

Ma Q . Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport. 2001; 12(8):1589-91. DOI: 10.1097/00001756-200106130-00015. View

Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L . 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 2001; 909(1-2):112-20. DOI: 10.1016/s0006-8993(01)02645-2. View

Gomez-Mancilla B, Cutler N, Leibowitz M, Spierings E, Klapper J, Diamond S . Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia. 2001; 21(7):727-32. DOI: 10.1046/j.1468-2982.2001.00208.x. View

Goldstein D, Roon K, Offen W, Ramadan N, Phebus L, Johnson K . Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001; 358(9289):1230-4. DOI: 10.1016/s0140-6736(01)06347-4. View

Goadsby P, Lipton R, Ferrari M . Migraine--current understanding and treatment. N Engl J Med. 2002; 346(4):257-70. DOI: 10.1056/NEJMra010917. View

Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L . Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia. 2002; 22(2):112-6. DOI: 10.1046/j.1468-2982.2002.00324.x. View

Olesen J, Diener H, Husstedt I, Goadsby P, Hall D, Meier U . Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11):1104-10. DOI: 10.1056/NEJMoa030505. View

10.

Brain S, Grant A . Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004; 84(3):903-34. DOI: 10.1152/physrev.00037.2003. View

11.

Petersen K, Birk S, Lassen L, Kruuse C, Jonassen O, Lesko L . The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25(2):139-47. DOI: 10.1111/j.1468-2982.2004.00830.x. View

12.

Petersen K, Lassen L, Birk S, Lesko L, Olesen J . BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005; 77(3):202-13. DOI: 10.1016/j.clpt.2004.10.001. View

13.

Rahmann A, Wienecke T, Hansen J, Fahrenkrug J, Olesen J, Ashina M . Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008; 28(3):226-36. DOI: 10.1111/j.1468-2982.2007.01497.x. View

14.

Schytz H, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M . PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2008; 132(Pt 1):16-25. DOI: 10.1093/brain/awn307. View

15.

Goadsby P . The vascular theory of migraine--a great story wrecked by the facts. Brain. 2008; 132(Pt 1):6-7. DOI: 10.1093/brain/awn321. View

16.

Schytz H, Schoonman G, Ashina M . What have we learnt from triggering migraine?. Curr Opin Neurol. 2010; 23(3):259-65. DOI: 10.1097/WCO.0b013e328337b884. View

17.

Nelson D, Phebus L, Johnson K, Wainscott D, Cohen M, Calligaro D . Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30(10):1159-69. DOI: 10.1177/0333102410370873. View

18.

Harmar A, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna J . Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012; 166(1):4-17. PMC: 3415633. DOI: 10.1111/j.1476-5381.2012.01871.x. View

19.

Humphrey P, Feniuk W, Perren M, Beresford I, Skingle M, Whalley E . Serotonin and migraine. Ann N Y Acad Sci. 1990; 600:587-98; discussion 598-600. DOI: 10.1111/j.1749-6632.1990.tb16912.x. View

20.

Mitsikostas D, Tfelt-Hansen P . Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Cent Nerv Syst Agents Med Chem. 2012; 12(4):241-9. DOI: 10.2174/187152412803760627. View